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sTATE-OF-THE-ART PAPER1621Nephrogenic Systemic Fibrosisndreas Kribben, Oliver Witzke, Uwe Hillen, Jörg Barkhausen, Anton E. Daul, Raimund Erbel
his overview summarizes the current knowledge about the pathogenesis, diagnosis, and
herapy for nephrogenic systemic fibrosis (NSF). NSF is characterized by skin induration that
egins in the extremities. Involvement of internal organs occurs, which ultimately leads to
eath. Exposure to gadolinium-based magnetic resonance (MR) contrast media, especially in
atients with renal dysfunction, seems to be the inciting event. To reduce the risk of NSF,
adolinium-based MR contrast media should be avoided in patients with renal failure unless
he diagnostic information is essential and not available with other imaging techniques.LATE-BREAKING CLINICAL TRIAL ATE-BREAKING CLINICAL TRIAL1629Improved Mortality Seen With DES in Registry of Medicare Patientsamela S. Douglas, J. Matthew Brennan, Kevin J. Anstrom, Art Sedrakyan, Eric L. Eisenstein,
hazala Haque, David Dai, David F. Kong, Bradley Hammill, Lesley Curtis, David Matchar,
alph Brindis, Eric D. Peterson
ouglas and colleagues combined datasets from the National Cardiovascular Data Registry
ites for coronary percutaneous coronary intervention (PCI) during 2004 to 2006 with
edicare inpatient claims data for follow-up outcomes. Drug-eluting stents (DES) were
mplanted in 217,675 patients and bare-metal stents (BMS) in 45,025 patients. At 30 months
nd after propensity score adjustment, DES patients had lower rates of death (13.5% vs.
6.5%, hazard ratio [HR]: 0.75) and myocardial infarction (7.5 of 100 patients vs. 8.9 of 100
atients, HR: 0.77), with minimal differences in revascularization, stroke, and bleeding. The
ES survival benefit was observed in all subgroups analyzed and persisted throughout follow-
p. In this largest ever real-world study, patients receiving DES had significantly better
linical outcomes than their BMS counterparts, without an associated increase in bleeding or
troke.(continued on page A-20)
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sLINICAL TRIALS1642Coronary CTA for Early Triage of Patients With Acute Chest PainEditorial Commentdo Hoffmann, Fabian Bamberg, Claudia U. Chae, John H. Nichols, Ian S. Rogers, Sujith K. Seneviratne,
uynh A. Truong, Ricardo C. Cury, Suhny Abbara, Michael D. Shapiro, Jamaluddin Moloo, Javed Butler,
aros Ferencik, Hang Lee, Ik-Kyung Jang, Blair A. Parry, David F. Brown, James E. Udelson,
tephan Achenbach, Thomas J. Brady, John T. Nagurney
offmann and colleagues performed coronary computed tomography angiography (CTA) in
atients who presented to the emergency room with acute chest pain and were at low or
ntermediate risk for acute coronary syndromes (ACS). The results of the coronary CTA were
ot shared with the treating physicians. Of almost 400 subjects enrolled, 8% had ACS.
ensitivity and negative predictive value for ACS were both 100% for subjects with no
oronary artery disease (CAD) on coronary CTA; there were no complications during the 6
onths of follow-up in these subjects. Both the extent of coronary plaque and the presence of
tenosis predicted ACS independently and incrementally to Thrombolysis In Myocardial
nfarction risk score. In this study, patients with acute chest pain and low to intermediate
ikelihood of ACS who are free of CAD by coronary CTA may be candidates for early
ischarge.NTERVENTIONAL CARDIOLOGY1653Less Coronary Endothelial Dysfunction With ZES Compared With SESin Won Kim, Hong Seog Seo, Jae Hyoung Park, Jin Oh Na, Cheol Ung Choi, Hong-Eui Lim,
ung Ju Kim, Seung-Woon Rha, Chang Gyu Park, Dong Joo Oh
im and colleagues studied coronary endothelial dysfunction 6 months after stent
mplantation in patients randomzied to either a zotarolimus-eluting stent (ZES), a sirolimus-
luting stent (SES), or a bare-metal stent (BMS). Endothelial function was assessed with
ncremental acetylcholine (Ach) and nitrate infusions and quantitatively measured both
roximal and distal to the stent. More intense vasoconstriction to Ach was seen with SES
han with ZES; both were more pronounced than BMS. Endothelium-independent
asodilation to nitrate did not differ. ZES seems to provoke less endothelial dysfunction in
he distal coronary artery compared with SES.NTERVENTIONAL CARDIOLOGY1660Examining the Effects of Diabetes on Rates of Restenosisle Fröbert, Bo Lagerqvist, Jörg Carlsson, Johan Lindbäck, Ulf Stenestrand, Stefan K. James
röbert and colleagues used the SCAAR (Swedish Angiography and Angioplasty Registry) to
valuate the impact of diabetes mellitus (DM) on restenosis rates in patients treated with a
ariety of different drug-eluting stents (DES) in a real-world setting. The rate of restenosis
as 1.2 times higher in patients with DM compared to patients without DM. There were
ignificant differences among the stents; the rate of restenosis in subjects with DM was 2
imes higher with the zotarolimus-eluting compared to the other stents. In this large real-
orld registry, DM significantly increased the risk of restenosis; further studies are needed to
etermine if zotarolimus increases the risk of restenosis in DM or if this finding reflected
election bias in this nonrandomized study.(continued on page A-23)
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gNTERVENTIONAL CARDIOLOGY1668Meta-Analysis Suggests Equivalency of GP IIb/IIIa Inhibitors for Primary PCI
DEATH                                                           
xif( ROthgieW)dexif( ROseluceloMllamSbamixicbAydutS ed)
IC %59%IC %59N/nN/n
Favors Abciximab Favors Small Molecules
DANZI               0/50           0/50        Not estimable
ERNST               0/30           1/29        7.01 0.31 [0.01, 7.96]        
EVA-AMI              7/201          8/226       33.95 0.98 [0.35, 2.76]        
FATA                5/341          7/351       31.75 0.73 [0.23, 2.33]        
MULTISTRATEGY      9/372          4/372       18.23 2.28 [0.70, 7.47]        
STRATEGY            3/88           2/87        9.07 1.50 [0.24, 9.20]        
Total (95% CI) 24/1082         22/1115 100.00 1.14 [0.64, 2.04]
Test for heterogeneity: Chi² = 2.66, df = 4 (P = 0.62) , I² = 0%
Test for overall effect: Z = 0.44 (P = 0.66)
0.1 0.2 0.5 1 2 5 10
Editorial Commentiuseppe De Luca, Grazia Ucci, Ettore Cassetti, Paolo Marino
hile the addition of glycoprotein (GP) IIb/IIIa inhibitors have shown improved
utcomes in ST-segment elevation myocardial infarction (STEMI) patients treated
ith primary percutaneous coronary intervention (PCI) in most studies, it is unclear
f abciximab is superior to the small molecule agents tirofiban and eptifibatide. De
uca and colleagues performed a meta-analysis of 6 trials that randomized over 2,000
rimary PCI patients to either abciximab or a small molecule agent. There were no
ignificant differences in rates of post-procedural Thrombolysis In Myocardial
nfarction flow grade 3, ST-segment resolution, reinfarction, or 30-day mortality.
his meta-analysis shows that among STEMI patients undergoing primary PCI,
oth abciximab and small molecule GP IIb/IIIa inhibitors have similar efficacy for
ngiographic, electrocardiographic, and clinical outcomes.NTERVENTIONAL CARDIOLOGY1677Meta-Analysis Shows Improved Outcomes for STEMI Patients Treated With DESomjot S. Brar, Martin B. Leon, Gregg W. Stone, Roxana Mehran, Jeffrey W. Moses, Simerjeet K. Brar,
eorge Dangas
he primary aim of the analysis by Brar and colleagues was to compare outcomes by
tent type for death, myocardial infarction (MI), target vessel revascularization
TVR), and stent thrombosis in randomized trials of ST-segment elevation
yocardial infarction (STEMI) patients. Thirteen randomized trials with over 7,000
ubjects were identified. Compared with bare-metal stents (BMS), drug-eluting stents
DES) significantly reduced TVR without increasing death, MI, or stent thrombosis.
hen reports were included from 18 registries that enrolled STEMI patients
n  26,521), DES significantly reduced TVR without an increase in MIs. Death
as significantly lower in the DES group within 1 year of the index PCI, but there
ere no differences within 2 years. In conclusion, the use of DES appears safe and
fficacious in randomized trials and registries of patients with STEMI.RRHYTHMIAS AND HEART FAILURE1690Low Rates of Use of Evidence-Based Therapies in Patients With AF and HFobby Nieuwlaat, Luc W. Eurlings, John G. Cleland, Stuart M. Cobbe, Panos E. Vardas,
lessandro Capucci, José L. Lo´pez-Sendòn, Joan G. Meeder, Yigal M. Pinto, Harry J. G. M. Crijns
trial fibrillation (AF) and heart failure (HF) often coexist in patients and are
nown to worsen each other’s prognosis. Little is known about how this combination
ffects the use of evidence-based therapies in clinical practice. The Euro Heart
urvey on AF, followed over 5,000 patients with AF from 35 countries. At baseline,
ne-third of these subjects had HF. The presence of AF was associated with a
eduction in the use of guideline-recommended therapy for HF with left ventricular
ystolic dysfunction (LVSD), such as beta-blockers or angiotensin-converting enzyme
nhibitors. The combination of AF and LVSD appears to reduce the use of
uideline-recommended drug therapy for both conditions.
(continued on page A-24)
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rARDIAC IMAGING1699MDCT May Be More Useful for Studying Peri-Infarct Tissue Than Cardiac MRIarl H. Schuleri, Marco Centola, Richard T. George, Luciano C. Amado, Kristine S. Evers,
akuya Kitagawa, Andrea L. Vavere, Robert Evers, Joshua M. Hare, Christopher Cox, Elliot R. McVeigh,
oão A. C. Lima, Albert C. Lardo
he use of cardiac multidetector computed tomography (MDCT) has been expanded beyond
he assessment of coronary atherosclerosis to include myocardial viability by delayed-contrast
nhancement (DE). Schuleri and colleagues compared MDCT and cardiac magnetic
esonance imaging (MRI) to evaluate the peri-infarct zone (PIZ) in a porcine model. DE-
DCT demonstrated excellent correlation of infarct size with post-mortem pathology and
E-MRI. DE-MDCT and -MRI both detected a PIZ in all animals, which correlated to a
ixture of viable and nonviable myocytes by histology. Further studies showed that DE-MDCT
rovided a more detailed assessment that was less susceptible to partial volume effects than MRI.ARDIAC IMAGING1708Positive Coronary Artery Remodeling Detected by MRIEditorial Commentuilian Miao, Shaoguang Chen, Robson Macedo, Shenghan Lai, Kiang Liu, Debiao Li, Bruce A. Wasserman,
ens Vogel-Clausen, João A. C. Lima, David A. Bluemke
oronary artery disease (CAD) is currently defined as clinically significant when luminal
arrowing is present. However, in early atherosclerosis, the first arterial changes consist of
ompensatory enlargement of both the outer wall of the vessel and the lumen (positive
emodeling). Miao and colleagues reviewed data from magnetic resonance imaging (MRI) in
he MESA trial to determine if positive remodeling could be identified with MRI in
symptomatic subjects. Positive remodeling was confirmed with increases in both vessel size
outer diameter) and lumen area that correlated with increases in wall thickness. This study
onfirms that coronary wall MRI can detect arterial remodeling in subjects with subclinical
therosclerosis.FROM AROUND THE WORLD OCUS ON INDIA
1718ultimodality Intervention Significantly
Improves Cardiac Risk Factors in Indian Population34.1
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Baseline Final orairaj Prabhakaran, Panniyammakal Jeemon, Shifalika Goenka, Ramakrishnan Lakshmy,
. R. Thankappan, Faruq Ahmed, Prashant P. Joshi, B. V. Murali Mohan, Ramanathan Meera,
ohas S. Das, Ramesh C. Ahuja, Ram Kirti Saran, Vivek Chaturvedi, K. Srinath Reddy
rabhakaran and colleagues hypothesized that a comprehensive program for cardiovascular
isease (CVD) risk factor reduction could be successful on a large scale. The intervention was
multipronged strategy of health promotion, high-risk primary prevention, and policy-level
r environmental changes, such as banning smoking in buildings and changing menu items
vailable at cafeterias. Favorable changes were observed in all of the CVD risk factors over
early 4 years of follow-up; these changes included an almost 10% reduction in blood sugar
nd a 3% reduction in systolic blood pressure, compared to increases of 13% and 8%,
espectively, in the control population. This comprehensive worksite-based intervention
rogram was effective in reducing CVD risk factors, and would likely be cost-effective by
educing cardiovascular events.
